#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, May 9 '26)

 

Antimicrob Agents Chemother

1. SULEA T, Stuible M, Moreno M, Pelletier A, et al
   Multifunctional ACE2-nanobody fusion design for pan-specific neutralization and cardiovascular protection in SARS coronavirus infection.
   Antimicrob Agents Chemother. 2026;70:e0002426.
   PubMed         Abstract available
   
   

   
   Antiviral Res

2. CHIBA S, Kiso M, Yamayoshi S, Uraki R, et al
   Niclosamide inhibits the replication of highly pathogenic avian influenza A (H5Nx) viruses and antiviral-resistant mutants.
   Antiviral Res. 2026;251:106421.
   PubMed         Abstract available
   
   

   
   Cell

3. HAVENS JL, Kosakovsky Pond SL, Zehr JD, Pekar JE, et al
   Dynamics of natural selection preceding human viral epidemics and pandemics.
   Cell. 2026;189:2762-2775.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

4. MORTON LC, Forshey BM, Klinkhammer KE, Romaner A, et al
   Local genomic epidemiology investigations of SARS-CoV-2 during the early pandemic response: A global systematic review.
   Epidemiol Infect. 2026;154:e56.
   PubMed         Abstract available
   
   

   
   J Gen Virol

5. SANTOS IA, Grosche VR, Oliveira LDS, Guarda PHS, et al
   Copper(II) benzyloxychalcone analogues as new potential metallodrugs against SARS-CoV-2 replication.
   J Gen Virol. 2026;107:002245.
   PubMed         Abstract available
   
   
6. ISLAM MT, Pillatzki A, Webb B, Ramamoorthy S, et al
   Infectivity of recombinant Torque teno sus virus 1 in pigs coinfected with swine influenza virus.
   J Gen Virol. 2026;107:002264.
   PubMed         Abstract available
   
   
7. SCHAFERS J, Warren CJ, Yang J, Zhang J, et al
   Stability of influenza viruses in the milk of cows and sheep.
   J Gen Virol. 2026;107:002257.
   PubMed         Abstract available
   
   

   
   J Infect

8. BEHARIER O, Guedalia J, Sehtman-Shachar DR, Kerem L, et al
   Maternal SARS-CoV-2 Infection and Early Child Growth and Development: A Nationwide Cohort Study.
   J Infect. 2026 Apr 17:106749. doi: 10.1016/j.jinf.2026.106749.
   PubMed         Abstract available
   
   
9. PEREZ-MAZZALI M, Perez-Cozar F, Cal-Sabater P, Rybakowska P, et al
   Persistent T cell phenotypic alterations and early innate immune dysregulation as potential biomarkers of Long COVID.
   J Infect. 2026 Mar 17:106731. doi: 10.1016/j.jinf.2026.106731.
   PubMed         Abstract available
   
   

   
   J Virol

10. ZHANG L, Hoffmann M, Pohlmann S
    Lock out: targeting TMPRSS2 to block influenza and coronaviruses.
    J Virol. 2026 May 4:e0080725. doi: 10.1128/jvi.00807.
    PubMed         Abstract available
    
    

    
    MMWR Morb Mortal Wkly Rep

11. KIBIGER L, Oltean HN, Leitz L, Krause E, et al
    Fatal Human Case of Highly Pathogenic Avian Influenza A(H5N5) in a Backyard Flock Owner - Washington, November 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:221-225.
    PubMed         Abstract available
    
    
12. VAUGHAN A, Joyce A, Traub E, Jae M, et al
    Serologic Evidence of Highly Pathogenic Avian Influenza A(H5N1) Virus Infection in a Veterinary Professional Exposed to an Infected Domestic Cat - Los Angeles County, California, December 2024-January 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:215-220.
    PubMed         Abstract available
    
    

    
    N Engl J Med

13. LITE TL, Goya S, Davis ML, Morris AE, et al
    Human Infection with Highly Pathogenic Avian Influenza A(H5N5) Virus.
    N Engl J Med. 2026 May 7. doi: 10.1056/NEJMc2518178.
    PubMed        
    
    
14. LEROUX-ROELS I, Huang G, Ferguson M, Kohli A, et al
    Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults.
    N Engl J Med. 2026;394:1803-1813.
    PubMed         Abstract available
    
    

    
    PLoS Biol

15. CAMPBELL AJ, Shephard M, Paulos AP, Pauly MD, et al
    Surveillance on California dairy farms reveals multiple possible sources of H5N1 influenza virus transmission.
    PLoS Biol. 2026;24:e3003761.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

16. MCTIERNAN J, Zhang Y, Li S, Kuhlman TE, et al
    Clustering of SARS-CoV-2 membrane proteins in lipid bilayer membranes.
    PLoS Comput Biol. 2026;22:e1014229.
    PubMed         Abstract available
    
    

    
    PLoS Med

17. O'HAGAN A, Pechey R, Forde H, Bandy L, et al
    Adherence to voluntary UK sugar, salt, and calorie reduction targets in the highest-grossing restaurant chains: A cross-sectional study.
    PLoS Med. 2026;23:e1004681.
    PubMed         Abstract available
    
    
18. KRUK ME, Kapoor NR, Arsenault C, Carai S, et al
    Health system use and experience among people with poor mental health: A cross-sectional analysis of the People's Voice Survey in 18 countries.
    PLoS Med. 2026;23:e1004745.
    PubMed         Abstract available
    
    

    
    PLoS One

19. DO NASCIMENTO AI, Dos Santos Conrado D, Mareto LK, de Azevedo MV, et al
    Age and vaccine information sources drive vaccine hesitancy: A household survey in Central-Western Brazil.
    PLoS One. 2026;21:e0348412.
    PubMed         Abstract available
    
    
20. SIEBELS K, Ogden NH, Turgeon P, Lapeyre J, et al
    The impact of non-pharmaceutical interventions on the socio-economic and demographic determinants of COVID-19 incidence: A spatial analysis of the pandemic in Toronto, Canada.
    PLoS One. 2026;21:e0347649.
    PubMed         Abstract available
    
    
21. CHU L, Hollar TL, Klimas N, Bertolli J, et al
    Facilitators of and barriers to participation in Long COVID research: A qualitative analysis.
    PLoS One. 2026;21:e0346007.
    PubMed         Abstract available
    
    
22. WEATHERALD J, Wen C, Sharpe H, Leung WM, et al
    Impact of the COVID-19 pandemic on sex-related disparities in cystic fibrosis healthcare utilization and outcomes: A population study.
    PLoS One. 2026;21:e0345009.
    PubMed         Abstract available
    
    
23. BIR C, Jung J, Widmar NO
    Understanding why people value working from home or hybrid workplace flexibility a study of preferences during the COVID-19 pandemic.
    PLoS One. 2026;21:e0348206.
    PubMed         Abstract available
    
    
24. KABATA Y, Terauchi R, Nakano T
    Nationwide trends and regional variation in intravitreal injections and anti-VEGF agent use in Japan from 2017 to 2022: An analysis of the NDB Open Data.
    PLoS One. 2026;21:e0348087.
    PubMed         Abstract available
    
    
25. PARK JH, Lee MT, Jung SY, Choi ST, et al
    Association between coronavirus disease 2019 and new-onset autoimmune diseases during the early phase of the pandemic.
    PLoS One. 2026;21:e0347872.
    PubMed         Abstract available
    
    
26. TORREJON-GUIRADO MC, Baena-Jimenez MA, Lima-Serrano M
    Association between cannabis use and result of COVID-19 testing among scholarised adolescents in Andalusia: A cross-sectional study.
    PLoS One. 2026;21:e0347098.
    PubMed         Abstract available
    
    
27. COSKUNER AKTAS S
    Work-family conflict in times of crisis: The moderating roles of self-efficacy and time-based spousal support during pandemic-induced remote work.
    PLoS One. 2026;21:e0348368.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

28. WAN Z, Yu L, Yang Z, Luo S, et al
    Stag2-mediated chromatin dynamics regulates antibody class switch recombination.
    Proc Natl Acad Sci U S A. 2026;123:e2536391123.
    PubMed         Abstract available
    
    

    
    Vaccine

29. BEOGO I, Muray M, Kibret TC, Xu Y, et al
    Between racism and rumors: understanding vaccine mistrust among older racially diverse adults in Canada.
    Vaccine. 2026;82:128611.
    PubMed         Abstract available
    
    
30. CONNER TL, Goguet E, Haines-Hull H, Segard A, et al
    mRNA COVID-19 vaccination induces minimal IgA in saliva in the absence of prior clinical or subclinical infection.
    Vaccine. 2026;82:128612.
    PubMed         Abstract available
    
    
31. SARNAIK AY, Khan ZU, Rajeswaran T, Majoe A, et al
    The role of misinformation in COVID-19 vaccine hesitancy in low- & middle-income countries.
    Vaccine. 2026;82:128595.
    PubMed         Abstract available
    
    
32. PAUL KK, Torres M, Shih STF, Gray RT, et al
    Estimating the cost-effectiveness of respiratory syncytial virus (RSV) vaccination program for older Australian adults.
    Vaccine. 2026;82:128591.
    PubMed         Abstract available
    
    
33. GULATI RR, Yaqub F, Goodman AL
    Enhancing uptake of respiratory vaccinations in asthma and chronic obstructive pulmonary disease (COPD) patients: a systematic review.
    Vaccine. 2026;81:128560.
    PubMed         Abstract available
    
    
34. WU JD, Meng H, Guo XL, Liu L, et al
    The immune response of the mRNA vaccine CS-2034 as a heterologous booster before and after breakthrough infection: A follow-up study.
    Vaccine. 2026;81:128575.
    PubMed         Abstract available
    
    
35. HIRAKAWA T, Yamada G, Tokiya M, Furukawa T, et al
    Impact of pre-vaccination active vitamin D levels on COVID-19 mRNA vaccine-induced immunity in a Japanese cohort.
    Vaccine. 2026;81:128576.
    PubMed         Abstract available
    
    
36. KONLAN M, Bhandari R, Owusu SA, Kubio C, et al
    The effect of the COVID-19 pandemic on routine childhood immunization coverage and dropout: A community-based cross-sectional study in the Tamale Metropolis, Ghana.
    Vaccine. 2026;81:128584.
    PubMed         Abstract available
    
    
37. REYNALDI A, Lee WS, Selva KJ, Audsley J, et al
    Immune responses associated with protection from SARS-CoV-2 infection.
    Vaccine. 2026;81:128579.
    PubMed         Abstract available
    
    
38. HIGGINS RA, Mazarakis N, Sun C, Toh ZQ, et al
    Effect of time-of-day vaccination on the antibody response to mRNA and protein COVID-19 vaccine in adults.
    Vaccine. 2026;81:128574.
    PubMed         Abstract available
    
    
39. GASHEMA P, Iradukunda PG, Rudacogora JC, Siddig EE, et al
    Unlocking Africa's vaccine Independence: The critical role of technology transfer and intellectual property.
    Vaccine. 2026;81:128573.
    PubMed         Abstract available
    
    
40. HAVERKATE MR, van de Kassteele J, van den Hof S, Sanders JG, et al
    The effect of pre-booked appointments on COVID-19 vaccine uptake among previously vaccinated older adults during the 2023 autumn campaign in the Netherlands: a regression discontinuity analysis.
    Vaccine. 2026;81:128565.
    PubMed         Abstract available
    
    

    
    Virology

41. ZHU M, Wang R, Li X, Zhou H, et al
    Canine influenza virus at the human-animal interface: origins, adaptive evolution, and implications for public health.
    Virology. 2026;621:110943.
    PubMed         Abstract available
    
    
42. LIU C, Yuan X
    Respiratory viruses as key drivers of pulmonary fibrosis: integrated pathways from barrier injury to immune-fibrotic crosstalk.
    Virology. 2026;620:110913.
    PubMed         Abstract available
    
    
43. SULLIVAN-HILL B, Shahrudin S, Ashley CL, Shields NJ, et al
    SARS-CoV-2 variant-specific enhancement of dendritic heparan sulfate mimetic antiviral activities.
    Virology. 2026;620:110915.
    PubMed         Abstract available
    
    
44. KIMURA R, Hayashi Y, Fujimoto-Sato Y, Ishii H, et al
    Decoding viral evolution through integrative bioinformatics: From genomes to global health.
    Virology. 2026;620:110920.
    PubMed         Abstract available
    
    

    
    Virus Res

45. WANG X, Guo J, Liu J, Jiang J, et al
    Shared genetic structure between COVID-19 and migraine: insights from large-scale genome-wide cross-trait analysis.
    Virus Res. 2026;367:199708.
    PubMed         Abstract available
    
    
46. NAGHIBOSADAT M, Hahn E, Molinaro S, Babuadze G, et al
    Comparison of SARS-CoV-2 variant pathogenicity in a long-COVID Syrian hamster model.
    Virus Res. 2026;367:199711.
    PubMed         Abstract available
    
    
47. SITHOLE MN, Khan MR, Mohammed HA, Khan RA, et al
    A Systematic Review on Vaccine Developmental Approaches: Evaluating Efficacy, and Addressing Challenges of Infectious Diseases in the Post-COVID-19 Era.
    Virus Res. 2026 Apr 1:199720. doi: 10.1016/j.virusres.2026.199720.
    PubMed         Abstract available
    
    
48. LIU Y, Wang C, Yan D, Zhang Y, et al
    Prognostic prediction in COVID-19 patients: a comprehensive analysis of gut microbiota and hematological biomarkers.
    Virus Res. 2026;367:199729.
    PubMed         Abstract available
    

Efficacy and #Safety of an #mRNA Seasonal #Influenza #Vaccine in Adults

 

Abstract

Background

Seasonal influenza causes substantial illness and death in adults 50 years of age or older, even with current vaccines. An investigational messenger RNA (mRNA)–based vaccine called mRNA-1010 encodes hemagglutinin glycoproteins from World Health Organization–recommended influenza strains.

Methods

In this phase 3, double-blind, active-controlled trial, we randomly assigned adults 50 years of age or older to receive trivalent mRNA-1010 (37.5 μg, which includes 12.5 μg of each strain) or a licensed standard-dose comparator. The primary efficacy end point was relative vaccine efficacy against reverse-transcriptase–polymerase-chain-reaction (RT-PCR)–confirmed, protocol-defined influenza-like illness caused by influenza A or B, from at least 14 days after vaccination through the end of the influenza season. Hypothesis testing was conducted hierarchically to assess noninferiority (lower boundary of the 95% confidence interval [CI], >−10%), superiority (lower boundary of the 95% CI, >0%), and a higher level of superiority (lower boundary of the 95% CI, >9.1%).

Results

A total of 40,703 participants received mRNA-1010 (20,350 participants) or the standard-dose comparator (20,353 participants); the median follow-up was 181 days (range, 1 to 227). RT-PCR–confirmed, protocol-defined influenza-like illness was observed in 411 of 20,179 recipients of mRNA-1010 (2.0%) and 557 of 20,124 recipients of the standard-dose comparator (2.8%), which corresponds to a relative vaccine efficacy of 26.6% (95% CI, 16.7 to 35.4), thereby meeting the criteria for noninferiority, superiority, and higher-level superiority. Solicited adverse reactions were more frequent with mRNA-1010 than with the standard-dose comparator (injection-site pain in 65.8% vs. 29.8%, fatigue in 45.1% vs. 20.3%, headache in 37.8% vs. 18.0%, and myalgia in 35.4% vs. 11.6%); most reactions were mild to moderate and transient. Serious adverse events were reported in 2.2% of the recipients of mRNA-1010 (with three events considered by the investigator to be vaccine-related) and in 1.9% of the recipients of the standard-dose comparator (with two events considered by the investigator to be vaccine-related).

Conclusions

In this trial, mRNA-1010 was superior to standard-dose licensed vaccines for prevention of RT-PCR–confirmed, protocol-defined influenza-like illness in adults 50 years of age or older. Solicited adverse reactions were more frequent with mRNA-1010. (Funded by Blackstone Life Sciences and Moderna; Fluent ClinicalTrials.gov number, NCT06602024.)

Source: 

Link: https://www.nejm.org/doi/full/10.1056/NEJMoa2516491?query=TOC

____

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, May 2 '26)

 

Biochem Biophys Res Commun

1. SAKTHI P, Arun K, Priya D
   Integrative network pharmacology and molecular simulation analysis reveals the therapeutic potential of Coscinium fenestratum alkaloids against SARS-CoV-2.
   Biochem Biophys Res Commun. 2026;817:153681.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

2. TOZDUMAN B, Gulle BT
   Influenza Vaccination Coverage and Determinants of Vaccination Among Older Adults in Turkey.
   Epidemiol Infect. 2026 Apr 30:1-17. doi: 10.1017/S0950268826101563.
   PubMed        
   
   

   
   J Gen Virol

3. CHIANG HL, Lin HT, Chen WY, Liang KH, et al
   Broadly neutralizing monoclonal antibodies derived from mRNA LNP immunization exhibit potent neutralizing ability against JN.1, KP.3.1.1 and XEC new Omicron variants.
   J Gen Virol. 2026;107:002251.
   PubMed         Abstract available
   
   

   
   J Immunol

4. BENEZECH S, Picq L, Villard M, Rousseaux N, et al
   Single-cell analysis identifies CPT1a-associated metabolic remodeling in human NK cells during COVID-19.
   J Immunol. 2026;215:vkag036.
   PubMed         Abstract available
   
   

   
   J Infect Dis

5. O'HALLORAN A, Hood N, Ujamaa D, Merced-Morales A, et al
   Effects of age and birth cohort on influenza A virus subtype-specific hospitalization rates, United States 2010-2025.
   J Infect Dis. 2026 Apr 27:jiag232. doi: 10.1093.
   PubMed         Abstract available
   
   
6. ISHIKAWA S, Okada N, Fukui Y, Ueha R, et al
   Respiratory Syncytial Virus-Mediated Gas6/Axl Axis Induces Hyporesponsive Macrophages to Promote Pneumococcal Proliferation in the Nasopharynx.
   J Infect Dis. 2026;233:674-684.
   PubMed         Abstract available
   
   
7. ESNEAU C, Boettiger D, Leask S, Bryant NE, et al
   The Pandemic Respiratory Virus Epidemiological Surveillance Trial - A Self-swab Surveillance System for Respiratory Viruses Nested Within FluTracking.
   J Infect Dis. 2026;233:e1031-e1039.
   PubMed         Abstract available
   
   
8. KLAASSEN F, Swartwood NA, Chitwood MH, Lopes R, et al
   National- and State-level SARS-CoV-2 Immunity Trends From January 2020 to December 2023: a Mathematical Modeling Analysis.
   J Infect Dis. 2026;233:714-724.
   PubMed         Abstract available
   
   

   
   J Virol

9. DAINES R, Sadeyen J-R, Chang P, Iqbal M, et al
   Mapping hemagglutinin residues driving antigenic diversity in H5Nx avian influenza viruses.
   J Virol. 2026 Apr 30:e0009526. doi: 10.1128/jvi.00095.
   PubMed         Abstract available
   
   

   
   Lancet

10. DU X, Anderson CS
    Off-target benefits of influenza vaccination in cardiovascular disease - Authors' reply.
    Lancet. 2026;407:1600.
    PubMed        
    
    
11. FROBERT O, Pedersen IB, Hjelholt AJ, Erikstrup C, et al
    Off-target benefits of influenza vaccination in cardiovascular disease.
    Lancet. 2026;407:1599-1600.
    PubMed        
    
    

    
    Pediatrics

12. ENGSTROM EE, Kaplan SL, Barson WJ, Lin PL, et al
    Pneumococcal Pneumonia in Hospitalized Children: 2017-2023.
    Pediatrics. 2026;157:e2025073196.
    PubMed         Abstract available
    
    
13. KUTZ C, Alarcon-Andrade G, Aguilera E, Garfias C, et al
    Incidence and Severity of Type 1 Diabetes in Children Through the COVID-19 Pandemic in Chile.
    Pediatrics. 2026 Apr 23:e2025072191. doi: 10.1542/peds.2025-072191.
    PubMed         Abstract available
    
    
14. JACOBSON KB, Merchant M, Fireman B, Klein NP, et al
    SARS-CoV-2 Vaccination Before and During Pregnancy and Prevention of Infant COVID-19 Infection.
    Pediatrics. 2026 Apr 22:e2025073000. doi: 10.1542/peds.2025-073000.
    PubMed         Abstract available
    
    
15. LOWENSTEIN C, Kamdar N, Rehkopf DH
    Trends in Youth Mental Health Among Patients in Family Medicine Practices: 2017-2023.
    Pediatrics. 2026;157:e2025072305.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

16. MOSS R, Tobin RJ, O'Hara-Wild M, Adekunle AI, et al
    Ensemble forecasts of COVID-19 activity to support Australia's pandemic response: 2020-22.
    PLoS Comput Biol. 2026;22:e1014199.
    PubMed         Abstract available
    
    
17. PAMORNCHAINAVAKUL N, Schroeder DC, VanderWaal K
    QoALa: A comprehensive workflow for viral quasispecies diversity comparison using long-read sequencing data.
    PLoS Comput Biol. 2026;22:e1014208.
    PubMed         Abstract available
    
    

    
    PLoS One

18. THIPAYAMASKOMON C, Grimaud O, Tattevin P, Lamhaut L, et al
    High-speed trains versus air transport vectors for mass transfers of critically ill patients: The TRANSCOV cohort study.
    PLoS One. 2026;21:e0348090.
    PubMed         Abstract available
    
    
19. HU R, Valdivia A, White T, Ju W, et al
    Poldip2 deficiency attenuates lung disease severity in a mouse model of COVID-19.
    PLoS One. 2026;21:e0348065.
    PubMed         Abstract available
    
    
20. OKADA Y, Nishiura H
    Changes in life expectancy and life span equality during the COVID-19 epidemic in 2020-22 in Japan.
    PLoS One. 2026;21:e0345579.
    PubMed         Abstract available
    
    
21. RODRIGUEZ-CRESPO JJ, Gutierrez-Leon E, Dammann-Beltran P, Seaman-Gomez JA, et al
    Outcomes in acute pulmonary embolism and their association with adherence to international recommendations around COVID-19 pandemic-induced hospital-strain: The experience in a Mexican tertiary care center.
    PLoS One. 2026;21:e0347761.
    PubMed         Abstract available
    
    
22. HASHEMPOUR Y, Zazouli MA, Jaafarzadeh N, Valadan R, et al
    Integrated monitoring of enveloped viruses in hospital environments: Detection, persistence, and implications for infection control.
    PLoS One. 2026;21:e0345644.
    PubMed         Abstract available
    
    
23. SU B, Sun Z, Chen R, Liu H, et al
    Association between psychological distress, lifestyle and career planning on health-related quality of life among the university students during school closure of COVID-19 pandemic in China.
    PLoS One. 2026;21:e0347032.
    PubMed         Abstract available
    
    
24. WANG M, Laison EKE, Philippsen T, Ghaemi S, et al
    Mechanistic modelling of highly pathogenic avian influenza: A scoping review revealing critical gaps in cross-species transmission models.
    PLoS One. 2026;21:e0347929.
    PubMed         Abstract available
    
    
25. FATHELRAHMAN E, Mohamed Ali M, Challa TG, Osman R, et al
    Modeling and assessing Highly Pathogenic Avian Influenza (HPAI) spread, epidemiological control measures, and cost.
    PLoS One. 2026;21:e0340004.
    PubMed         Abstract available
    
    
26. BASHIR K, Ouedraogo MO, Dharma C, Sobers M, et al
    Strengthening access to and confidence in COVID-19 vaccines among equity-deserving populations across Canada: An exploratory qualitative study.
    PLoS One. 2026;21:e0301953.
    PubMed         Abstract available
    
    
27. KO CC, Wu JY, Hung KC, Liao SW, et al
    The impact of COVID-19 vaccination on long-term risk of new-onset atrial fibrillation/flutter after COVID-19 infection: A retrospective cohort study.
    PLoS One. 2026;21:e0348133.
    PubMed         Abstract available
    
    
28. LIU C, Yang L, Lei J
    CMAP-Fusion: A cross-modal feature selection and model pruning framework for laboratory and imaging data.
    PLoS One. 2026;21:e0346875.
    PubMed         Abstract available
    
    
29. DAS N, Konduru L, Dahia SS, Sagnika S, et al
    The stress reduction potential of Bhagavad Gita and Yoga for healthcare workers during the COVID-19 pandemic: A randomized controlled trial.
    PLoS One. 2026;21:e0347320.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

30. RODRIGUEZ HERNANDEZ CJ, Cruz-Cruz A, Shrestha CL, Terekhova M, et al
    Gingipain proteases from the bacterium Porphyromonas gingivalis confer protection against airway viral infection.
    Proc Natl Acad Sci U S A. 2026;123:e2503100123.
    PubMed         Abstract available
    
    
31. HUANG KA, Nguyen HTV, Chen YY, Wu KJ, et al
    Broad neutralization of influenza B hemagglutinin antibodies via receptor mimicry and glycan engagement.
    Proc Natl Acad Sci U S A. 2026;123:e2532989123.
    PubMed         Abstract available
    
    
32. ZHANG Y, Wang C, Zheng Y, Chen F, et al
    An Ad5-vectored platform generating self-assembling VLPs elicits potent mucosal immunity against influenza A virus and SARS-CoV-2.
    Proc Natl Acad Sci U S A. 2026;123:e2519857123.
    PubMed         Abstract available
    
    
33. DE LACY N, Lam WY, Collins T, Danks D, et al
    A century of suicide: Insights from long-term data in the United States.
    Proc Natl Acad Sci U S A. 2026;123:e2519951123.
    PubMed         Abstract available
    
    

    
    Vaccine

34. LIU Y, Jia M, Mu X, Jiang B, et al
    Designing equitable influenza vaccination services for older adults in rural China: A discrete choice experiment.
    Vaccine. 2026;82:128590.
    PubMed         Abstract available
    
    
35. SILVA LL, Lopes VDS, da Silva DCB, Nemer CRB, et al
    Global overview of vaccine trust: Evidence from a scoping review.
    Vaccine. 2026;79:128482.
    PubMed         Abstract available
    
    
36. JAMES E, Christie S, Boye B, Githieya D, et al
    How to leverage social media to build confidence in COVID-19 vaccines: findings and lessons learned from nationwide campaigns in four countries.
    Vaccine. 2026;79:128475.
    PubMed         Abstract available
    
    
37. MALDEN DE, Ackerson BK, Gee J, Peryer MA, et al
    Self-reported reactogenicity of RSV vaccines among older adults: a post-licensure study within a large integrated healthcare system in Southern California.
    Vaccine. 2026;79:128493.
    PubMed         Abstract available
    
    
38. FANTIN R, Das S, Loria V, Calderon A, et al
    Hybrid immunity provides stronger protection against SARS-CoV-2 infection than vaccination alone: Evidence from a population-based active monitoring study.
    Vaccine. 2026;79:128506.
    PubMed         Abstract available
    
    
39. DENG L, Barton B, Choi P, Clarke L, et al
    Clinical, psychological and quality of life outcomes up to 12-months following thrombosis with thrombocytopenia syndrome after ChAdOx1-S (AZD1222) vaccination in Australia.
    Vaccine. 2026;79:128501.
    PubMed         Abstract available
    
    
40. BRIGGS K, Gingerich MC, Gingerich A, Johnson SK, et al
    Intranasal PIV5-vectored SARS-COV-2 KP.2 vaccine protects against homologous and heterologous challenge in mice and hamsters.
    Vaccine. 2026;79:128490.
    PubMed         Abstract available
    
    
41. AZEEZ R, Ames SR, Lotoski LC, Winsor GL, et al
    Predictors of SARS-CoV-2 anti-Spike IgG antibody levels following two COVID-19 vaccine doses among children and adults in the Canadian CHILD Cohort.
    Vaccine. 2026;79:128342.
    PubMed         Abstract available
    
    
42. ROOYAKKERS A, Ye L, Cahn PE, Ruiz-Palacios GM, et al
    Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomized, double blinded phase 3 trial.
    Vaccine. 2026;79:128424.
    PubMed         Abstract available
    
    
43. STRAUTINS K, Foong R, Carcione D, Spencer P, et al
    Post-licensure safety monitoring of nirsevimab in Western Australia 2024.
    Vaccine. 2026;79:128468.
    PubMed         Abstract available
    
    
44. AIZAWA Y, Shobugawa Y, Tachikawa J, Ikuse T, et al
    Effectiveness of the COVID-19 messenger RNA vaccine against symptomatic omicron infection in children aged 6 months to 11 years in Japan.
    Vaccine. 2026;79:128474.
    PubMed         Abstract available
    
    
45. LLOYD PC, Shah PB, Zhang HT, Shah N, et al
    Safety monitoring of health outcomes following RSVPreF3 + AS01 and RSVPreF vaccination among Medicare beneficiaries aged 65 years and older in the United States, 2023-2024.
    Vaccine. 2026;79:128459.
    PubMed         Abstract available
    
    
46. MADNI SA, Olson CK, Zauche LH, Machefsky A, et al
    Risk of perinatal death and preterm birth among an observational cohort of women vaccinated against SARS-CoV-2 in pregnancy: CDC COVID-19 vaccine pregnancy registry.
    Vaccine. 2026;79:128461.
    PubMed         Abstract available
    
    
47. GIOVANATTI A, Shapiro AE
    Anticipating tuberculosis vaccine acceptability in Kenya and South Africa: a narrative review of behavioral and social drivers and strategies to optimize acceptability.
    Vaccine. 2026;79:128457.
    PubMed         Abstract available
    
    
48. GUARDALINI LGO, Martins IM, Bernardino TC, Quintilio W, et al
    Non-clinical analysis of virus-like particles (VLP) containing SARS-CoV-2 vaccine antigens.
    Vaccine. 2026;79:128406.
    PubMed         Abstract available
    
    
49. DURIER C, Benhamouda N, Besbes A, Lefebvre M, et al
    Ancestral Wuhan SARS-CoV-2 anti-spike CD4(+) T cells predict protection from symptomatic omicron breakthrough infection.
    Vaccine. 2026;79:128425.
    PubMed         Abstract available
    
    
50. VISKUPIC F, Wiltse DL, Liebl Z, Kinslow T, et al
    The prevalence and nature of anti-vaccination legislation in ten midwestern states: Implications for public health and policy.
    Vaccine. 2026;79:128452.
    PubMed         Abstract available
    
    
51. DRISLANE S, Lake J, Attwell K
    Learning from government communication strategies to promote infant RSV immunisation: A cross-national study of France, Luxembourg, Spain, and Australia.
    Vaccine. 2026;79:128432.
    PubMed         Abstract available
    
    
52. CABIESES B, Obach A, Madrid P, Blukacz A, et al
    Mapping the continuum of COVID-19 vaccine acceptance and hesitancy in Chile: Insights from qualitative research among nationals and migrants.
    Vaccine. 2026;79:128433.
    PubMed         Abstract available
    
    
53. LU PJ, Hung MC, Srivastav A, Kriss JL, et al
    RSV vaccination uptake by the end of the 2024-25 respiratory virus season among adults aged 60-74 years at increased risk of severe RSV and adults aged >/=75 years.
    Vaccine. 2026;79:128427.
    PubMed         Abstract available
    
    
54. JANSSEN RS, Coffman RL
    A narrative review of immune-mediated adverse events in clinical trials of CpG oligonucleotide toll-like receptor 9 agonists.
    Vaccine. 2026;79:128437.
    PubMed         Abstract available
    
    
55. IRVING SA, Crane B, Daley MF, Dixon BE, et al
    2023-2024 COVID-19 vaccination coverage in pregnancy in ten healthcare delivery organizations in the United States.
    Vaccine. 2026;79:128441.
    PubMed         Abstract available
    
    
56. COSTANTINO V, Notaras A, MacIntyre CR
    Long COVID in children in Australia and the potential impact of vaccination.
    Vaccine. 2026;79:128442.
    PubMed         Abstract available
    
    
57. LLANES-KIDDER C, Gaythorpe K, Rawson T
    Sociodemographic factors influencing COVID-19 vaccine uptake and dropout rates in England.
    Vaccine. 2026;79:128477.
    PubMed         Abstract available
    
    
58. MCEVOY R, Hervol JR, Zhang Y, Wagner EM, et al
    A modified self-controlled case series on mortality risk following primary series doses of COVID-19 vaccines in U.S. Medicare beneficiaries aged 65 years and older.
    Vaccine. 2026;79:128460.
    PubMed         Abstract available

Prior #immunity to seasonal #influenza #H3N2 virus confers varying levels of cross - #protection against challenge with clade 2.3.4.4b #H5N1, #H7N9, or #H9N2 virus in a #ferret model

 

ABSTRACT

Evaluating how prior immunity to seasonal influenza viruses influences subsequent zoonotic influenza A virus (IAV) infection in animal models is critical for pandemic preparedness. In this study, we investigated the cross-protective effect of pre-existing A(H3N2) immunity in ferrets challenged with three distinct subtypes of zoonotic IAVs: low pathogenic A(H7N9) and A(H9N2) viruses, and highly pathogenic clade 2.3.4.4b A(H5N1) virus. Our results show that A(H3N2) preimmunity conferred some protection against A(H5N1) and A(H9N2) virus infection, as evidenced by more rapid viral clearance in the upper respiratory tract, reduced virus shedding in the nasal wash on select days post-inoculation, and a lowered frequency of viral detection in specific tissues compared with naive animals. In contrast, A(H3N2) preimmunity provided minimal cross-protection against A(H7N9) infection, as weight loss and viral dissemination in tissues were not significantly reduced in A(H3N2) preimmune ferrets relative to naive animals. These findings highlight the variable breadth and magnitude of cross-protection elicited by prior seasonal IAV immunity against zoonotic influenza virus challenges in the ferret model. Seasonal influenza A(H3N2) preimmunity provided differing levels of cross-protection against zoonotic influenza A virus infections in ferrets.

Source: 

Link: https://journals.asm.org/doi/10.1128/spectrum.03974-25

____

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, April 25 '26)

 

Ann Intern Med

1. LIM SY, Lee J, Chang E, Kwon JS, et al
   Neither Metformin nor Ursodeoxycholic Acid Effectively Treats Postacute Sequelae of COVID-19 : A Randomized Clinical Trial.
   Ann Intern Med. 2026 Mar 3. doi: 10.7326/ANNALS-25-04883.
   PubMed         Abstract available
   
   
2. QASEEM A, Obley AJ, Yost J, Abraham GM, et al
   Outpatient Treatment of Confirmed COVID-19 in Symptomatic Adults: Living, Rapid Practice Points From the American College of Physicians (Version 3).
   Ann Intern Med. 2026 Feb 10. doi: 10.7326/ANNALS-25-03766.
   PubMed         Abstract available
   
   
3. SOMMER I, Dobrescu A, Gadinger A, Sharifan A, et al
   Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Review for the American College of Physicians (Version 3).
   Ann Intern Med. 2026 Feb 10. doi: 10.7326/ANNALS-25-03691.
   PubMed         Abstract available
   
   

   
   Biochemistry

4. MEDEIROS-SILVA J, Zhang Y, Hong M
   Phosphatidylinositol Interactions with the SARS-CoV-2 Envelope Protein Investigated by Lipid (13)C Labeling and Solid-State NMR.
   Biochemistry. 2026;65:1178-1191.
   PubMed         Abstract available
   
   

   
   J Infect

5. COX SN, Bennett JC, Casto AM, Hoffman KL, et al
   INFLUENZA HOUSEHOLD TRANSMISSION AND GENOMIC DIVERSITY IN THE UNITED STATES: A PROSPECTIVE COHORT STUDY, 2022-2024.
   J Infect. 2026 Apr 20:106748. doi: 10.1016/j.jinf.2026.106748.
   PubMed         Abstract available
   
   

   
   J Virol

6. ZHANG R, Jian X, Zhang Y, Sun Y, et al
   The oral nucleoside analogue inhibitor VV251 effectively inhibits coinfection by respiratory syncytial virus and influenza A virus.
   J Virol. 2026 Apr 21:e0000626. doi: 10.1128/jvi.00006.
   PubMed         Abstract available
   
   
7. YILDIZ S, El Zahed SS, Villalon-Letelier F, Wang Q, et al
   Re-engineering segment 8 facilitates generation of a versatile live-attenuated influenza A virus vector platform for secretory protein delivery.
   J Virol. 2026 Apr 21:e0034726. doi: 10.1128/jvi.00347.
   PubMed         Abstract available
   
   
8. KONG W, Zhang J, Song Y, Song J, et al
   Disruption of spike protein N-glycosylation induces its endoplasmic reticulum retention and attenuates SARS-CoV-2 infectivity.
   J Virol. 2026 Mar 30:e0027026. doi: 10.1128/jvi.00270.
   PubMed         Abstract available
   
   
9. XIU R, Wang Y, Cai W, Wang Q, et al
   Potent in vitro synergistic antiviral effects of the pan-coronavirus fusion inhibitor EK1 in combination with RBD-specific antibodies or M(pro) inhibitors.
   J Virol. 2026 Mar 30:e0007626. doi: 10.1128/jvi.00076.
   PubMed         Abstract available
   
   
10. BRENNAN JW, Wang G, Connor S, Wang X, et al
    A respiratory syncytial virus trailer sequence modulates viral replication and the generation and propagation kinetics of copy-back defective viral genomes.
    J Virol. 2026;100:e0018426.
    PubMed         Abstract available
    
    
11. ADAM A, Wu W, Jones MC, Hao H, et al
    Respiratory syncytial virus infection induces heterologous protection against SARS-CoV-2 through gammadelta T cell-mediated trained immunity and the activation of SARS-CoV-2-reactive mucosal T cells.
    J Virol. 2026 Mar 18:e0165825. doi: 10.1128/jvi.01658.
    PubMed         Abstract available
    
    

    
    MMWR Morb Mortal Wkly Rep

12. BELL JM, Barbre K, Meng L, Lape-Newman B, et al
    Influenza Vaccination Coverage Among Nursing Home Residents and Health Care Personnel - United States, 2024-25 Influenza Season.
    MMWR Morb Mortal Wkly Rep. 2026;75:195-201.
    PubMed         Abstract available
    
    

    
    N Engl J Med

13. BUTLER CC, Pinto AD, Harris V, Holmes J, et al
    Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.
    N Engl J Med. 2026;394:1583-1594.
    PubMed         Abstract available
    
    

    
    Pediatrics

14. SEGEV N, Wilson E, Moehlman M, Corathers SD, et al
    Unmasking Adrenal Insufficiency: Adrenal Crisis Triggered by Influenza-Associated Encephalitis.
    Pediatrics. 2026 Apr 22:e2025072983. doi: 10.1542/peds.2025-072983.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

15. LI Y, Nielsen BF, Levin SA, Te Velthuis AJW, et al
    Spatio-temporal modelling of in vitro influenza A virus infection: The impact of defective interfering particles on the type I interferon response.
    PLoS Comput Biol. 2026;22:e1014198.
    PubMed         Abstract available
    
    
16. WHITE LA, Leon TM
    Forecastability of infectious disease time series: are some seasons and pathogens intrinsically more difficult to forecast?
    PLoS Comput Biol. 2026;22:e1014175.
    PubMed         Abstract available
    
    

    
    PLoS One

17. ORTEGA-MARTIN E, Alvarez-Galvez J
    Understanding quality-of-life patterns in long COVID: How Symptoms and socioeconomic conditions shape patient wellbeing.
    PLoS One. 2026;21:e0347743.
    PubMed         Abstract available
    
    
18. CHAVES SS, Castells VB, Mira-Iglesias A, Puig-Barbera J, et al
    Rhinovirus/enterovirus contribution to respiratory-associated hospitalizations in adults during respiratory seasons in Spain: A 6-year prospective study.
    PLoS One. 2026;21:e0347659.
    PubMed         Abstract available
    
    
19. LEE J, Bajiya VP, Jung E
    Vaccination scenario-based study on seasonal influenza in Republic of Korea.
    PLoS One. 2026;21:e0322686.
    PubMed         Abstract available
    
    
20. PIRZADA P, Wilde A, Doherty GH, Harris-Birtill D, et al
    Understanding older adults' perception, acceptance, and adoption of smart home technologies.
    PLoS One. 2026;21:e0345563.
    PubMed         Abstract available
    
    
21. FANG Z, Xu H, Mu Y
    Risk-taking responses to crash experience: Evidence from China.
    PLoS One. 2026;21:e0347543.
    PubMed         Abstract available
    
    
22. GARZA J, Sebastian R, Cover B, Sanchez A, et al
    Nicotine dependence among critically ill COVID-19 patients: A population-based cohort study.
    PLoS One. 2026;21:e0308776.
    PubMed         Abstract available
    
    
23. MCDONALD C, Grajales AG, Yahia NA, Fisman D, et al
    Healthcare resource utilization and cost burden of COVID-19 according to vaccination status in adults in Ontario, Canada, 2021-2023.
    PLoS One. 2026;21:e0344690.
    PubMed         Abstract available
    
    
24. LOVATO N, Appleton SL, Reynolds AC, Gill TK, et al
    Relationships between pre-pandemic mental health, sociodemographic factors and health behaviours in older adults during the acute onset of COVID-19 in Australia: A descriptive analysis.
    PLoS One. 2026;21:e0346787.
    PubMed         Abstract available
    
    
25. AUDUREAU E, Jean C, Layese R, Neuraz A, et al
    Association between parenthood and survival among 30,386 patients hospitalized with COVID-19.
    PLoS One. 2026;21:e0346679.
    PubMed         Abstract available
    
    
26. IPEKCI AM, Hodel EM, Filsinger M, Wegmuller S, et al
    Who would take part in a pandemic preparedness cohort study? The role of vaccine-related affective polarisation: Cross-sectional survey.
    PLoS One. 2026;21:e0346420.
    PubMed         Abstract available
    
    
27. YANG Z, Imouza A, Puelma Touzel M, Amadoro C, et al
    Regional and temporal patterns of partisan polarization during the COVID-19 pandemic in the United States and Canada.
    PLoS One. 2026;21:e0347327.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

28. SANDERS CG, Liu M, Fusco JA, Ohl EM, et al
    Efficient replication of influenza D virus in the human airway underscores zoonotic potential.
    Proc Natl Acad Sci U S A. 2026;123:e2530325123.
    PubMed         Abstract available
    
    

    
    Vaccine

29. ROBERTSON AH, Wolf AS, Fossum E, Solum G, et al
    Long-lasting cross-reactive and polyfunctional SARS-CoV-2 T cell responses in seniors are maintained after repeated vaccination and infections.
    Vaccine. 2026;80:128511.
    PubMed         Abstract available
    
    
30. DLOUHY P, Petras M, Lesna IK, Macalik R, et al
    Transient elevation of NT-proBNP after mRNA COVID-19 vaccination in healthy adults: A longitudinal biomarker analysis.
    Vaccine. 2026;80:128535.
    PubMed         Abstract available
    
    
31. VAN DE BURGWAL LHM, Pronker ES, Herz J
    Australia's vaccine legacy: Time for a boost? Mapping an innovation system in a fragmented data environment.
    Vaccine. 2026;80:128525.
    PubMed         Abstract available
    
    
32. WU D, Liu K
    Cost and effectiveness of COVID-19 vaccination strategies during the 2023 post-reopening omicron wave in Xinjiang, Western China: Evidence from SIR and Markov models.
    Vaccine. 2026;80:128536.
    PubMed         Abstract available
    
    
33. MAEDA H, Saito N, Igarashi A, Ishida M, et al
    Effectiveness of JN.1-adapted COVID-19 vaccine against medically attended SARS-CoV-2 infection and COVID-19 hospitalization in adults in Japan, from October 2024 to April 2025: VERSUS.
    Vaccine. 2026;80:128544.
    PubMed         Abstract available
    
    
34. MORO PL, Romanson B, Marquez P, Zhang B, et al
    Adverse events after Pfizer's Respiratory Syncytial Virus Vaccine in pregnant women in the Vaccine Adverse Event Reporting System, 2024-2025, United States.
    Vaccine. 2026;80:128547.
    PubMed         Abstract available
    
    
35. QUINTANAR-SOLARES M, Fleming JA, Musau W, Mulati F, et al
    RSV ready? Exploring feasibility and acceptability of RSV immunization options in low- and middle-income countries.
    Vaccine. 2026;80:128550.
    PubMed         Abstract available
    
    
36. KITANO T, Hashimoto E, Sado T, Yoshida S, et al
    Maternal effectiveness of respiratory syncytial virus using multicenter healthcare records: A retrospective cohort study.
    Vaccine. 2026;80:128566.
    PubMed         Abstract available
    
    
37. ZHANG L, Lin T, Wang M, Ma X, et al
    Effectiveness of prescription-based influenza vaccination services among older adults in Binzhou, China: A cluster-randomized controlled trial.
    Vaccine. 2026;82:128588.
    PubMed         Abstract available
    
    
38. FOLEGATTI PM, Pepin S, Tabar C, Fries K, et al
    Immunogenicity and safety of recombinant influenza vaccine versus standard inactivated influenza vaccine in children aged 3 to 8 years: results from a phase III randomised study.
    Vaccine. 2026;82:128582.
    PubMed         Abstract available
    
    
39. RICE E, Cheng AC, Britton PN, Carr J, et al
    Influenza epidemiology, treatment and prevention in Australian children: Trends from 6 years of PAEDS-FluCAN influenza surveillance (2019-2024).
    Vaccine. 2026;82:128592.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, April 19 '26)

 

Biochem Biophys Res Commun

1. CHEN M, Chen W, Jiang X, Liang S, et al
   Virtual screening targeting the conserved domain of the IAV M2 protein reveals the potential broad-spectrum anti-IAV activity of ajmaline.
   Biochem Biophys Res Commun. 2026;814:153643.
   PubMed         Abstract available
   
   

   
   BMJ

2. DAVIES SR, Davies AL, Higgins JPT, Caldwell DM, et al
   Effectiveness of interventions to increase vaccine uptake: component network meta-analysis.
   BMJ. 2026;393:e087578.
   PubMed         Abstract available
   
   

   
   Drug Saf

3. HWANG CS, Lu Z, Russo M, Zakoul H, et al
   Physician Awareness of FDA's Relaxation of REMS-Required Laboratory Testing Requirements and Changes in Prescribing Practices During the COVID-19 Pandemic.
   Drug Saf. 2026;49:519-528.
   PubMed         Abstract available
   
   
4. COATES MM, Rowe SL, Sullivan SG, Munoz FM, et al
   Assessing the Use of Medical Insurance Claims and Electronic Health Records to Measure COVID-19 Vaccination During Pregnancy.
   Drug Saf. 2026;49:567-580.
   PubMed         Abstract available
   
   
5. RACHWAL O, Gutierrez-Lobon M, Cueto NS, Ventura AN, et al
   Evaluating COVID-19 Vaccine Masking and Unmasking Methods in Two National Pharmacovigilance Databases.
   Drug Saf. 2026;49:581-590.
   PubMed         Abstract available
   
   
6. JAJOU R, van Puijenbroek E, Overbeek J, Hek K, et al
   GP Consultations for Herpes Zoster After COVID-19 Vaccination: A Self-Controlled Cohort Study Based on Electronic Health Record Data from the Netherlands.
   Drug Saf. 2026;49:529-539.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

7. GONZALES BE, Ochoa TJ, van der Sande MAB
   Inequalities in complete pneumococcal vaccination among Peruvian children before and after the COVID-19 pandemic: An evaluation using demographic and health surveys from 2018 to 2023.
   Epidemiol Infect. 2026;154:e49.
   PubMed         Abstract available
   
   
8. KIMURA M, Asai Y, Tsuzuki S, Shimizu Y, et al
   Effectiveness of voluntary PCR testing against COVID-19 spread in remote Japanese islands.
   Epidemiol Infect. 2026;154:e48.
   PubMed         Abstract available
   
   

   
   J Virol Methods

9. ASGHARI M, Golalipour M, Memarian A, Farazmandfar T, et al
   Presentation of multiple copies of a non-dominant surface epitope by circular RNA effectively induce an immune response against SARS-CoV-2.
   J Virol Methods. 2026;343:115378.
   PubMed         Abstract available
   
   
10. CHIBA S
    Therapeutic mechanisms of early oseltamivir administration in the management of mild COVID-19 through the sympathetic nervous system: A scoping review.
    J Virol Methods. 2026;343:115386.
    PubMed         Abstract available
    
    

    
    Lancet

11. JOHANSEN ND, Seco JP, Martinon-Torres F, Biering-Sorensen T, et al
    Unclear benefits of higher doses of influenza vaccine - Authors' reply.
    Lancet. 2026;407:1426.
    PubMed        
    
    
12. FLAHAULT A
    Unclear benefits of higher doses of influenza vaccine.
    Lancet. 2026;407:1425-1426.
    PubMed        
    
    

    
    PLoS Biol

13. SOLA I, Zuniga S
    New transcription signals in SARS-CoV-2 reshape virus-host interactions.
    PLoS Biol. 2026;24:e3003744.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

14. JEONG YD, Hart WS, Ishikane M, Kim KS, et al
    Identifying the optimal rapid antigen test for screening and determining the end of isolation: A modeling study.
    PLoS Comput Biol. 2026;22:e1013102.
    PubMed         Abstract available
    
    
15. ANOKYE F, Li MWZ, Walker S, Hurford A, et al
    Quantifying SARS-CoV-2 Omicron variant spread and the impact of non-pharmaceutical interventions in Newfoundland and Labrador, Canada.
    PLoS Comput Biol. 2026;22:e1013562.
    PubMed         Abstract available
    
    

    
    PLoS One

16. ABDELGHANY M, Yu F, Rennard S, Gwon Y, et al
    Bayesian reanalysis of early remdesivir for the treatment of COVID-19 in outpatients with high risk of progression to severe disease.
    PLoS One. 2026;21:e0346878.
    PubMed         Abstract available
    
    
17. BERBER E, Hanley HB, Gamez BM, Ross TM, et al
    Assessment of hemagglutinin-inhibition activity following influenza vaccination during the 2022-2023, 2023-2024, and 2024-2025 seasons.
    PLoS One. 2026;21:e0347314.
    PubMed         Abstract available
    
    
18. MURALIDHAR K, Ngaybe MGB, Pope B, Nanjaiah S, et al
    Behavioural and Social Drivers (BeSD) of COVID-19 vaccination for children: A cross-sectional study of parental vaccine confidence and intent in Mysore, India.
    PLoS One. 2026;21:e0316877.
    PubMed         Abstract available
    
    
19. BHUPATHI M, Hegde S, Molloy JC, Devarapu GCR, et al
    MobileLAMP: A low-cost, portable incubation device for isothermal nucleic acid amplification.
    PLoS One. 2026;21:e0346874.
    PubMed         Abstract available
    
    
20. SHIMAZU Y, Isoda N, Hiono T, Hew YL, et al
    Evaluation of therapeutic efficacy of baloxavir marboxil against high pathogenicity avian influenza virus infection in duck model.
    PLoS One. 2026;21:e0347205.
    PubMed         Abstract available
    
    
21. GANGAT R, Ngah V, Tawonga R, Blanford JI, et al
    Spatial and temporal patterns of SARS-CoV-2 infection in uMgungundlovu, KwaZulu-Natal, South Africa.
    PLoS One. 2026;21:e0317648.
    PubMed         Abstract available
    
    
22. VAN DUINKERKEN A, van der Velden PG, Duckers MLA, Baliatsas C, et al
    Revisiting the exposure criterion for PTSD: Using the COVID-19 pandemic as an opportunity to assess measurement invariance of PTSD symptoms across event types.
    PLoS One. 2026;21:e0347315.
    PubMed         Abstract available
    
    
23. KITTUR ME, Jones BDM, Imran S, Wang W, et al
    Impact of the COVID-19 pandemic on adults accessing specialist psychiatric care: A cross-sectional Canadian analysis.
    PLoS One. 2026;21:e0346913.
    PubMed         Abstract available
    
    
24. CASJENS S, Hovanec J, Glaser N, Massag J, et al
    Occupational risk factors for depression and anxiety symptoms: Insights from a large cohort study during and after the SARS-CoV-2 pandemic.
    PLoS One. 2026;21:e0346871.
    PubMed         Abstract available
    
    
25. JIANG KP, Bennett S, Yager P
    Heat-actuated valve implementation in a point-of-care, paper-based microfluidic device for infectious disease detection.
    PLoS One. 2026;21:e0344750.
    PubMed         Abstract available
    
    
26. ABBAS U, Laghari RN, Ahmed I, Musawwir UA, et al
    Acute SARS-CoV-2 viral load and systemic inflammation are associated with neuropsychiatric and musculoskeletal symptoms in long COVID.
    PLoS One. 2026;21:e0346978.
    PubMed         Abstract available
    
    
27. OZATO N, Hori S, Miyai N, Takase H, et al
    Association of visceral fat and plasmacytoid dendritic cell-derived interferon alpha with SARS-CoV-2 infection.
    PLoS One. 2026;21:e0344870.
    PubMed         Abstract available
    
    
28. DIAS GF, Fan C, Han M, Wang X, et al
    COVID-19 in hemodialysis patients: New insights into metabolomic profile dynamics from 60 days pre- to 60 days post-diagnosis.
    PLoS One. 2026;21:e0346687.
    PubMed         Abstract available
    
    
29. MOHTASHAM F, Hashemi Nazari SS, Pourhoseingholi MA, Kavousi K, et al
    Hybrid feature-selection and diversity-guided stacking framework for interpretable ensemble learning: Application to COVID-19 mortality prediction.
    PLoS One. 2026;21:e0341198.
    PubMed         Abstract available
    
    
30. LEE SJ, Kim J, Han M, Lee JA, et al
    Distinct plasma cytokine and chemokine profiles in severe COVID-19 and septic shock.
    PLoS One. 2026;21:e0347126.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

31. GOLDMAN N, Pebley AR
    The Latino health experience: Past and future.
    Proc Natl Acad Sci U S A. 2026;123:e2530795123.
    PubMed         Abstract available
    
    
32. HUOT M, Wang D, Shakhnovich E, Monasson R, et al
    Constrained evolutionary funnels shape viral immune escape.
    Proc Natl Acad Sci U S A. 2026;123:e2536956123.
    PubMed         Abstract available
    
    
33. FARIAS A, Bridgeman VL, Rodrigues FS, Puttur F, et al
    Type I interferons induced upon respiratory viral infection impair lung metastatic initiation.
    Proc Natl Acad Sci U S A. 2026;123:e2412919123.
    PubMed         Abstract available
    
    

    
    Vaccine

34. HSIEH SM, Choi MJ, Chen YC, Cheng SY, et al
    Cost-effectiveness of vaccination of older adults with an MF59(R)-adjuvanted quadrivalent influenza vaccine compared to standard-dose and high-dose vaccines in South Korea and Taiwan.
    Vaccine. 2026;80:128533.
    PubMed         Abstract available
    
    
35. ANYALECHI EG, Marquez PL, Rubin MN, Johannsen SP, et al
    Safety of seasonal inactivated influenza vaccines in children 6 months-17 years of age in the Vaccine Adverse Events Reporting System (VAERS) 2018-2023: before, during, and after the COVID-19 pandemic public health emergency.
    Vaccine. 2026;81:128569.
    PubMed         Abstract available
    
    

    
    Virology

36. SWIERKOT J, Tyczynska KM, Siemaszko J, Madej M, et al
    The association of selected genetic polymorphisms with adverse events following COVID-19 vaccination: a single-centre prospective observational cohort study.
    Virology. 2026;619:110876.
    PubMed         Abstract available
    
    
37. CHEN G, Liang D, Liu M, Lv Z, et al
    Theaflavins suppresses RSV infection by modulating the MAVS-I-IFN pathway.
    Virology. 2026;619:110872.
    PubMed         Abstract available
    
    
38. LIU R, Patterson L, Yeasmin M, Kim KH, et al
    Low-dose multivalent COVID-19 mRNA vaccines enhance broadly cross-reactive antibodies and protective immune responses of co-administered protein-based vaccines.
    Virology. 2026;619:110884.
    PubMed         Abstract available
    
    
39. WANG Z, Wongnak R, Oba M, Mizutani T, et al
    Omicron RBD expressed in E. coli outperforms mammalian-expressed S1 spike protein in generating highly neutralizing anti-SARS-CoV-2 antibodies in mice.
    Virology. 2026;619:110894.
    PubMed         Abstract available
    
    
40. RICHARDSON SAS, Boodhoo N, Bhat S, Wells J, et al
    Differential outcomes of viral co-infections with high pathogenicity avian influenza A(H5N6) and SARS-CoV-2 in mammalian in vitro systems.
    Virology. 2026;620:110912.
    PubMed         Abstract available